Oncology Brothers: Practice-Changing Cancer Discussions FDA Approval of Epcoritamab-Rituximab-Lenalidomide for R/R Follicular Lymphoma – Dr. Gilles Salles
Dec 4, 2025
Join lymphoma expert Dr. Gilles Salles from Memorial Sloan Kettering as he discusses the recent FDA approval of Epcoritamab for relapsed follicular lymphoma. He reveals the promising EPCOR FL1 trial results, showcasing a striking progression-free survival benefit. Dr. Salles dives into the bispecific nature of Epcoritamab, how it targets CD20 and CD3, and shares insights on side effects like cytokine release syndrome. He also discusses the implications of minimal residual disease testing and where Epcoritamab fits into future treatment strategies.
AI Snips
Chapters
Transcript
Episode notes
How Epcoritamab Works
- Epcoritamab is a CD20xCD3 bispecific that brings T cells to B cells to trigger tumor cell killing.
- This mechanism is similar to other bispecifics and explains its activity across B-cell malignancies.
Follow The Step‑Up Dosing Schedule
- Use a three‑step subcutaneous step‑up schedule during cycle one to reduce CRS risk before moving to full 48 mg dosing.
- Continue weekly dosing in cycles 2–3 then every 4 weeks from cycle 4 as per the study regimen.
Marked Efficacy Boost With Triplet
- Adding epcoritamab to R‑squared raised overall response from 74% to 89% and greatly prolonged PFS.
- The trial reported a hazard ratio of 0.21, suggesting substantially delayed progression versus R‑squared alone.